New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-21

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Current diagnostic tools such as interferon gamma release assay (IGRA) and purified protein derivative (PPD) can not distinguish patients with latent tuberculosis infection (LTBI) and persistence of live mycobacteria. This inability to rule out living mycobacteria in patients investigated for LTBI leads to unnecessary and potentially harmful treatment regimes all around the globe.

The goal of this observational study is to identify candidate biomarkers for viable bacilli in latent tuberculosis in order to decrease the use of unnecessary and ineffective antibiotic treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection

NCT06728930

Latent Tuberculosis Infection Tuberculosis Infection, Latent

ENROLLING_BY_INVITATION

The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

NCT06580639

Tuberculosis Immunologic Activity Alteration

RECRUITING

Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis

NCT06764576

Mycobacterial Infection Tuberculosis (TB)

RECRUITING

Training Protocol on the Natural History of Tuberculosis

NCT01212003

Mycobacterium Infections Tuberculosis, Multidrug-Resistant Latent Tuberculosis +2 more

RECRUITING

Improving the Diagnostic of Tuberculosis

NCT02861768

Tuberculosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberculosis (TB) is the second leading cause of death due to a single infectious agent, with the main burden in resource-limited settings and in vulnerable populations. It is estimated that approximately 25% of the global population is infected with TB. LTBI is a condition where the mycobacteria rests within the body instead of creating active disease. About half of the active TB cases develop within 2 years of exposure and the other half reactivates as distant as several decades post exposure. Persistence of viable bacilli is a prerequisite for the reactivation of TB.

Through sampling of peripheral blood the investigators will investigate how selected cytokines, enzyme activity and gene expression changes during course of treatment, 4-6 months, and during follow up, 1 year. These patterns will be compared to the patterns of patients with: latent TB without treatment, active TB with treatment as well as healthy controls. Samples will be drawn at 0, 1, 6 and 12 months, after treatment initialization when applicable. Healthy controls will only be sampled once. Most of the analysis will be performed on TB-antigen stimulated blood.

The investigators hypothesize that there is a substantial fraction of latent TB patients who do not harbor live mycobacteria and that this is reflected in study outcome measures when given treatment. Furthermore, the investigators hypothesize that this fraction of latent TB patients will resemble healthy controls in terms of outcome measures whereas their counterpart, latent TB patients harboring living bacteria, will not.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Latent Tuberculosis Persistent Infection Mycobacterium Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Latent TB on treatment

Treatment according to existing Swedish guidelines with:

Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months OR Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6 months

No interventions assigned to this group

Latent TB not on treatment

Latent TB without indication for treatment OR patient who do not want to receive treatment

No interventions assigned to this group

Active TB with treatment

Treatment according to existing Swedish guidelines. Duration and choice of antibiotic therapy depending on the condition.

No interventions assigned to this group

Healthy control

Healthy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* latent tuberculosis: Interferon gamma (IFN-γ) \>0.70 IU/ml in the Quantiferon-TB Plus assay
* age 15-25 years OR high likelihood of recent TB transmission
* informed consent

* age 15-25 years
* informed consent

* diagnosed with active TB
* informed consent

Exclusion Criteria

* active tuberculosis
* chronic illness
* immunosuppressive treatment
* pregnancy (including 6 months post-partum)
* previous treatment for either active or latent TB infection

Controls

* latent- OR active tuberculosis
* chronic illness
* immunosuppressive treatment
* pregnancy (including 6 months post-partum)
* previous treatment for either active or latent TB infection

Active TB

age \< 15 years

Minimum Eligible Age

15 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No